Gilead Sciences Inc SEC Filings

Gilead Sciences, Inc. reported an insider stock sale by its Chief Commercial Officer, Johanna Mercier. On 12/15/2025, Mercier sold 3,000 shares of Gilead common stock at $122 per share in a sale transaction coded "S".

After this sale, she beneficially owns 106,221 shares directly. The report notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, which allows executives to schedule trades in advance.

Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.

On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.

Gilead Sciences Chief Commercial Officer Johanna Mercier reported routine equity award activity involving restricted stock units and company shares. On 12/10/2025, 3,842 restricted stock units converted into an equal number of Gilead common shares. On the same date, 1,814 shares of common stock were disposed of in a transaction coded "F," indicating shares were withheld or used to cover tax obligations at a price of $121.34 per share.

After these transactions, Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units. Each restricted stock unit represents the contingent right to receive one share, and the units follow a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining units vesting 6.25% quarterly until fully vested.

Gilead Sciences reported a leadership change affecting its legal and corporate affairs functions. The company announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025. Her employment with the company will end later in December. This transition means Gilead will need to adjust leadership responsibilities in a key oversight and governance role, which can influence how the company manages legal risk, regulatory matters and external corporate communications.

Gilead Sciences, Inc. (GILD)11/17/2025, the CFO sold 2,500 shares of Gilead common stock at a price of $125.23 per share in an open-market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 154,555 shares of Gilead common stock in direct ownership. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, which is designed to allow insiders to trade according to predetermined instructions.

Gilead Sciences, Inc. (GILD) reported insider activity by its Chief Commercial Officer, Johanna Mercier. On 11/17/2025, she exercised a non-qualified stock option to acquire 25,000 shares of common stock at an exercise price of $66.64 per share, increasing her direct holdings before any sales.

That same day, she reported open-market sales of 25,524 shares at a weighted-average price of $125.8251 and 2,476 shares at a weighted-average price of $126.2575, all under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she directly owned 107,193 shares of Gilead common stock and 73,110 non-qualified stock options.

Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.

Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.

Gilead Sciences (GILD) filed its Q3 2025 10‑Q, reporting total revenue of $7.77 billion, up from $7.55 billion a year ago, and diluted EPS of $2.43 versus $1.00. Net income rose to $3.05 billion from $1.25 billion as operating income improved to $3.33 billion, reflecting lower charges versus last year and higher royalty and contract revenue.

Product sales were $7.35 billion (slightly below $7.52 billion last year). HIV remained the core driver at $5.28 billion, led by Biktarvy at $3.69 billion. Liver Disease rose to $819 million, while Veklury declined to $277 million. Oncology product sales were $788 million, with Cell Therapy at $432 million and Trodelvy at $357 million. The company recognized $400 million of previously constrained revenue tied to a sale of certain intellectual property, lifting royalty/contract revenue to $424 million. Cash and equivalents were $7.33 billion; operating cash flow for the nine months was $6.69 billion. Shares outstanding were 1,240,679,623 as of October 31, 2025.